Probing Tumour Proteostasis and the UPR with Serum Markers

Antoine Galmiche; Chloé Sauzay; Aline Houessinon; Bruno Chauffert; Olivier Pluquet

doi:10.1016/j.trecan.2016.04.004

Probing Tumour Proteostasis and the UPR with Serum Markers

Trends Cancer. 2016 May;2(5):219-221. doi: 10.1016/j.trecan.2016.04.004. Epub 2016 Apr 28.

Authors

Antoine Galmiche¹, Chloé Sauzay², Aline Houessinon², Bruno Chauffert³, Olivier Pluquet⁴

Affiliations

¹ Service de Biochimie, Centre de Biologie Humaine (CBH), CHU Amiens Sud, France; EA4666, Université de Picardie Jules Verne (UPJV), Amiens, France. Electronic address: [email protected].
² Service de Biochimie, Centre de Biologie Humaine (CBH), CHU Amiens Sud, France; EA4666, Université de Picardie Jules Verne (UPJV), Amiens, France.
³ EA4666, Université de Picardie Jules Verne (UPJV), Amiens, France; Service d'Oncologie Médicale, CHU Amiens Sud, France.
⁴ Université de Lille, Institut Pasteur de Lille, CNRS UMR8161 - M3T - Mechanisms of Tumourigenesis and Targeted Therapies, Lille, France.

PMID: 28741509
DOI: 10.1016/j.trecan.2016.04.004

Abstract

Tumour proteostasis and the unfolded protein response (UPR) are emerging drivers of tumour progression and important determinants of clinical efficacy of cancer therapy. Recent findings indicate that they also regulate the production of protein tumour markers. Here, we discuss how this new knowledge opens up new perspectives for cancer therapeutics.

Keywords: UPR; serum tumour markers; therapeutics; tumour proteostasis.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Biomarkers / blood*
Humans
Neoplasms / blood*
Neoplasms / drug therapy
Neoplasms / metabolism
Proteostasis*
Unfolded Protein Response*

Substances

Biomarkers